Literature DB >> 22526534

Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice.

K M Tobey1, D M Walentiny, J L Wiley, F I Carroll, M I Damaj, M R Azar, G F Koob, O George, L S Harris, R E Vann.   

Abstract

RATIONALE: Alleviating addiction to tobacco products could prevent millions of deaths. Investigating novel compounds selectively targeting α4β2 nAChRs hypothesized to have a key role in the rewarding effects of nicotine may be a useful approach for future treatment.
OBJECTIVES: The present study was designed to evaluate 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine (4-nitro-PFEB), a potent competitive antagonist of neuronal α4β2 nAChRs, in several animal models related to nicotine reward: drug discrimination, intracranial self-stimulation (ICSS), conditioned place preference, and limited access to self-administration.
METHODS: Long Evans rats were trained in a two-lever discrimination procedure to discriminate 0.4 mg/kg nicotine (s.c.) from saline. Male Sprague-Dawley rats were stereotaxically implanted with electrodes and trained to respond for direct electrical stimulation of the medial forebrain bundle. ICR mice were evaluated using an unbiased place preference paradigm, and finally, male Wistar rats were implanted with intrajugular catheters and tested for nicotine self-administration under limited access (1 h/day).
RESULTS: 4-Nitro-PFEB attenuated the discriminative stimulus effects of nicotine, but alone did not produce nicotine-like discriminative stimulus effects. Nicotine-induced facilitation of ICSS reward thresholds was reversed by 4-nitro-PFEB, which alone had no effect on thresholds. 4-Nitro-PFEB also blocked the conditioned place preference produced by nicotine, but alone had no effect on conditioned place preference. Finally, 4-nitro-PFEB dose-dependently decreased nicotine self-administration.
CONCLUSIONS: These results support the hypothesis that neuronal α4β2 nAChRs play a key role in mediating the rewarding effects of nicotine and further suggest that targeting α4β2 nAChRs may yield a potential candidate for the treatment of nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526534      PMCID: PMC3464481          DOI: 10.1007/s00213-012-2703-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

1.  Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.

Authors:  Janice W Smith; Adrian Mogg; Elisiana Tafi; Eleanor Peacey; Ian A Pullar; Philip Szekeres; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2006-11-18       Impact factor: 4.530

2.  The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice.

Authors:  Carrie L Walters; Sharon Brown; Jean-Pierre Changeux; Billy Martin; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

3.  In vivo characterization of a novel inhibitor of CNS nicotinic receptors.

Authors:  M Imad Damaj; Jenny L Wiley; Billy R Martin; Roger L Papke
Journal:  Eur J Pharmacol       Date:  2005-09-21       Impact factor: 4.432

4.  Differential behavioral responses to nicotine in Lewis and Fischer-344 rats.

Authors:  Scott D Philibin; Robert E Vann; Stephen A Varvel; Herbert E Covington; John A Rosecrans; John R James; Susan E Robinson
Journal:  Pharmacol Biochem Behav       Date:  2004-11-18       Impact factor: 3.533

5.  2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal alpha4beta2 nAChRs.

Authors:  Galya R Abdrakhmanova; M Imad Damaj; F Ivy Carroll; Billy R Martin
Journal:  Mol Pharmacol       Date:  2006-02-27       Impact factor: 4.436

6.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

7.  CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats.

Authors:  Olivier George; Sandy Ghozland; Marc R Azar; Pietro Cottone; Eric P Zorrilla; Loren H Parsons; Laura E O'Dell; Heather N Richardson; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-05       Impact factor: 11.205

8.  Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning.

Authors:  Jennifer A Davis; Justin W Kenney; Thomas J Gould
Journal:  J Neurosci       Date:  2007-10-03       Impact factor: 6.167

9.  Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists.

Authors:  Sheri D Grabus; Billy R Martin; Sharon E Brown; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2006-02-04       Impact factor: 4.530

10.  Nicotine dependence and reward differ between adolescent and adult male mice.

Authors:  D Kota; B R Martin; S E Robinson; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2007-04-19       Impact factor: 4.030

View more
  14 in total

1.  Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern
Journal:  Neuropsychopharmacology       Date:  2013-02-21       Impact factor: 7.853

Review 2.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

3.  Synthesis and nicotinic acetylcholine receptor in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues of 2'-fluoro-3'-(4-nitrophenyl)deschloroepibatidine.

Authors:  Pauline Ondachi; Ana Castro; Charles W Luetje; M Imad Damaj; S Wayne Mascarella; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2012-07-11       Impact factor: 7.446

4.  Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats.

Authors:  Kelen Freitas; F Ivy Carroll; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.157

5.  Highly Selective and Potent α4β2 nAChR Antagonist Inhibits Nicotine Self-Administration and Reinstatement in Rats.

Authors:  Jinhua Wu; Andrea Cippitelli; Yaohong Zhang; Ginamarie Debevec; Jennifer Schoch; Akihiko Ozawa; Yongping Yu; Huan Liu; Wenteng Chen; Richard A Houghten; Gregory S Welmaker; Marc A Giulianotti; Lawrence Toll
Journal:  J Med Chem       Date:  2017-12-13       Impact factor: 7.446

6.  Bupropion increases activation in nucleus accumbens during anticipation of monetary reward.

Authors:  Yumiko Ikeda; Takuya Funayama; Amane Tateno; Haruhisa Fukayama; Yoshiro Okubo; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2019-07-24       Impact factor: 4.530

7.  Effects of blockade of α4β2 and α7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats.

Authors:  Xiu Liu
Journal:  Int J Neuropsychopharmacol       Date:  2013-08-19       Impact factor: 5.176

8.  Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Authors:  Jesse S Rodriguez; Colin S Cunningham; Fernando B Moura; Pauline Ondachi; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

9.  Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects.

Authors:  Doran J Satanove; Simon Rahman; T M Vanessa Chan; Suelynn Ren; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2020-11-04       Impact factor: 4.530

10.  Iptakalim attenuates self-administration and acquired goal-tracking behavior controlled by nicotine.

Authors:  S Charntikov; N Swalve; S Pittenger; K Fink; S Schepers; G C Hadlock; A E Fleckenstein; G Hu; M Li; R A Bevins
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.